NCT03737994 2026-03-18Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting10 enrolled 17 charts
NCT03052608 2025-11-25A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCPfizerPhase 3 Active not recruiting296 enrolled 28 charts 1 FDA